IMO-T 2.13 CGI-T -0.07 AC-T -0.05 LNR-T 1.37 LLY-N 2.04 META-Q 0.82 NVDA-Q -0.21
Daily Stock Opinions and Ratings
Stockchase Opinions

Hugh Cleland, CFA YM BioSciences YM-T BUY Sep 07, 2006

The only biotech stock that he owns. Accumulates on weakness. Had 2 trials on their cancer drug without getting approval, but this isn't a concern. Statistically difficult to get approval in 2 tries. Is expecting a successful end point. Have a fantastic pipeline of other drugs as well.
Hugh Cleland, CFAHugh Cleland, CFA
Owned
Unlock Rating
$3.540

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

YM BioSciences(YM-T)

Jan 24, 2007
Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Behind that, Nimotuzumab is a great compound that has some interesting phase 2 trials. Great risk/reward.
Hugh Cleland, CFAHugh Cleland, CFA
Owned
Unlock Rating
$4.620

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

YM BioSciences(YM-T)

Feb 19, 2007
Was forced to cancel its cancer treatment trial. They do have some cash. Have another product in the pipeline, but it is in Cuba, which will keep US investors away.. It will take 6 months for the market to care again.
Peter HodsonPeter Hodson
No
Unlock Rating
$1.860

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

YM BioSciences(YM-T)

May 24, 2007
In spite of its setback, he still likes. Risks/reward at this point is not bad. Speculative.
Hugh Cleland, CFAHugh Cleland, CFA
Owned
Unlock Rating
$2.010

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

YM BioSciences(YM-T)

Mar 26, 2008
Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.
Geoff HoultonGeoff Houlton
No
Unlock Rating
$0.990

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

HRTG-N -0.007$18.863
EIF-T 0.37$48.84
MRK-N 0.35$78.35
MDI-T -0.11$8.3
DBM-T 0.03$6.86
Advertising

Today's Top Picks

IMO-T 2.13$88.37
CGI-T -0.07$33
AC-T -0.05$13.97
LNR-T 1.37$48.15
LLY-N 2.04$842

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

RH-N 0.12$161.25
LVMUY-… 0$109.54
NXPI-Q 0.18$170.92
DAL-N 0.07$40.92
AMD-Q -0.03$87.47

Most Recent Experts

Bruce Murray

The Murray Wealth Group

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Chris Blumas

at Raymond James Investment Counsel Ltd.

Stockchase Insights

5i Research

Advertising
Advertising
© Stockchase Inc.